Concord Biotech Limited — Investor Meet, 06-06-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Concord Biotech reported Q4 revenue up 35% at INR 430 Cr and FY25 revenue up 18% to INR 1,200 Cr. PAT grew 21% to INR 372 Cr with Q4 margins at 32.7%. API segment rose 37% in Q4 (14% FY growth), while Formulations grew 26% in Q4 and 38% for FY25, led by domestic strength and a new injectable facility. CDMO projects have started contributing, targeting double-digit sales. Capex is mostly complete; growth will come from existing capacity and product launches, with a focus on maintaining an 80:20 API-formulation mix and achieving ~25% CAGR.